F
9 Meters Biopharma, Inc.
NMTRQ
$0.00
$0.000.00%
E
Sell
3/14/2023Downgrade
9 Meters Biopharma, Inc. (NMTRQ) was downgraded to E+ from D- on 03/14/2023.
9 Meters Biopharma, Inc. (NMTRQ) was downgraded to E+ from D- on 03/14/2023.
D
Sell
2/23/2023Upgraded
9 Meters Biopharma, Inc. (NMTR) was upgraded to D- from E+ on 2/23/2023 due to an increase in the total return index and volatility index.
9 Meters Biopharma, Inc. (NMTR) was upgraded to D- from E+ on 2/23/2023 due to an increase in the total return index and volatility index.
E
Sell
2/8/2023Downgrade
9 Meters Biopharma, Inc. (NMTR) was downgraded to E+ from D- on 2/8/2023 due to a decline in the total return index, solvency index and volatility index. The quick ratio declined from 3.15 to 1.23.
9 Meters Biopharma, Inc. (NMTR) was downgraded to E+ from D- on 2/8/2023 due to a decline in the total return index, solvency index and volatility index. The quick ratio declined from 3.15 to 1.23.
D
Sell
5/23/2022Downgrade
9 Meters Biopharma, Inc. (NMTR) was downgraded to D- from D on 5/23/2022 due to a decline in the growth index, solvency index and valuation index. EBIT declined 24% from -$9.16M to -$11.36M, operating cash flow declined 22.3% from -$7.97M to -$9.75M, and the quick ratio declined from 5.56 to 4.53.
9 Meters Biopharma, Inc. (NMTR) was downgraded to D- from D on 5/23/2022 due to a decline in the growth index, solvency index and valuation index. EBIT declined 24% from -$9.16M to -$11.36M, operating cash flow declined 22.3% from -$7.97M to -$9.75M, and the quick ratio declined from 5.56 to 4.53.
D
Sell
5/16/2022Upgraded
9 Meters Biopharma, Inc. (NMTR) was upgraded to D from E+ on 5/16/2022 due to an increase in the volatility index and total return index.
9 Meters Biopharma, Inc. (NMTR) was upgraded to D from E+ on 5/16/2022 due to an increase in the volatility index and total return index.
E
Sell
5/13/2022Downgrade
9 Meters Biopharma, Inc. (NMTR) was downgraded to E+ from D on 5/13/2022 due to a decline in the total return index and volatility index.
9 Meters Biopharma, Inc. (NMTR) was downgraded to E+ from D on 5/13/2022 due to a decline in the total return index and volatility index.
D
Sell
5/4/2022Upgraded
9 Meters Biopharma, Inc. (NMTR) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index.
9 Meters Biopharma, Inc. (NMTR) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index.
E
Sell
5/1/2022Downgrade
9 Meters Biopharma, Inc. (NMTR) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index.
9 Meters Biopharma, Inc. (NMTR) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index.
D
Sell
4/21/2022Upgraded
9 Meters Biopharma, Inc. (NMTR) was upgraded to D from E+ on 4/21/2022 due to an increase in the valuation index.
9 Meters Biopharma, Inc. (NMTR) was upgraded to D from E+ on 4/21/2022 due to an increase in the valuation index.
E
Sell
4/20/2022Downgrade
9 Meters Biopharma, Inc. (NMTR) was downgraded to E+ from D on 4/20/2022 due to a significant decline in the total return index, solvency index and volatility index. The quick ratio declined from 7.36 to 5.56.
9 Meters Biopharma, Inc. (NMTR) was downgraded to E+ from D on 4/20/2022 due to a significant decline in the total return index, solvency index and volatility index. The quick ratio declined from 7.36 to 5.56.
D
Sell
11/9/2021Upgraded
9 Meters Biopharma, Inc. (NMTRQ) was upgraded to D from E+ on 11/09/2021.
9 Meters Biopharma, Inc. (NMTRQ) was upgraded to D from E+ on 11/09/2021.
E
Sell
11/8/2021Downgrade
9 Meters Biopharma, Inc. (NMTR) was downgraded to E+ from D on 11/8/2021 due to a decline in the volatility index.
9 Meters Biopharma, Inc. (NMTR) was downgraded to E+ from D on 11/8/2021 due to a decline in the volatility index.
D
Sell
1/7/2021Upgraded
9 Meters Biopharma, Inc. (NMTR) was upgraded to D from D- on 1/7/2021 due to a noticeable increase in the total return index and volatility index.
9 Meters Biopharma, Inc. (NMTR) was upgraded to D from D- on 1/7/2021 due to a noticeable increase in the total return index and volatility index.
D
Sell
11/12/2020Upgraded
9 Meters Biopharma, Inc. (NMTR) was upgraded to D- from E+ on 11/12/2020 due to a noticeable increase in the growth index, total return index and solvency index. Earnings per share increased from -$0.5675 to -$0.06, debt to equity declined from 1.47 to 0.36, and operating cash flow increased 32.86% from -$6.2M to -$4.16M.
9 Meters Biopharma, Inc. (NMTR) was upgraded to D- from E+ on 11/12/2020 due to a noticeable increase in the growth index, total return index and solvency index. Earnings per share increased from -$0.5675 to -$0.06, debt to equity declined from 1.47 to 0.36, and operating cash flow increased 32.86% from -$6.2M to -$4.16M.
E
Sell
8/14/2020Downgrade
9 Meters Biopharma, Inc. (NMTR) was downgraded to E+ from D- on 8/14/2020 due to a noticeable decline in the growth index, valuation index and total return index. Earnings per share declined from -$0.0875 to -$0.57, operating cash flow declined 135.44% from -$2.63M to -$6.2M, and EBIT declined 43% from -$4.27M to -$6.1M.
9 Meters Biopharma, Inc. (NMTR) was downgraded to E+ from D- on 8/14/2020 due to a noticeable decline in the growth index, valuation index and total return index. Earnings per share declined from -$0.0875 to -$0.57, operating cash flow declined 135.44% from -$2.63M to -$6.2M, and EBIT declined 43% from -$4.27M to -$6.1M.
D
Sell
6/2/2020Upgraded
9 Meters Biopharma, Inc. (NMTR) was upgraded to D- from E+ on 6/2/2020 due to an increase in the growth index and total return index.
9 Meters Biopharma, Inc. (NMTR) was upgraded to D- from E+ on 6/2/2020 due to an increase in the growth index and total return index.
E
Sell
5/15/2020Downgrade
9 Meters Biopharma, Inc. (NMTR) was downgraded to E+ from D- on 5/15/2020 due to a significant decline in the solvency index, efficiency index and growth index. The quick ratio declined from 0.31 to 0.17, and total capital declined 28.68% from -$6.39M to -$8.22M.
9 Meters Biopharma, Inc. (NMTR) was downgraded to E+ from D- on 5/15/2020 due to a significant decline in the solvency index, efficiency index and growth index. The quick ratio declined from 0.31 to 0.17, and total capital declined 28.68% from -$6.39M to -$8.22M.
D
Sell
3/10/2020Upgraded
Innovate Biopharmaceuticals, Inc. (INNT) was upgraded to D- from E+ on 3/10/2020 due to an increase in the volatility index.
Innovate Biopharmaceuticals, Inc. (INNT) was upgraded to D- from E+ on 3/10/2020 due to an increase in the volatility index.
E
Sell
2/24/2020Downgrade
Innovate Biopharmaceuticals, Inc. (INNT) was downgraded to E+ from D- on 2/24/2020 due to a decline in the growth index, solvency index and volatility index. Earnings per share declined from -$0.1321 to -$0.257, the quick ratio declined from 1.39 to 0.68, and EBIT declined 6.28% from -$6.12M to -$6.51M.
Innovate Biopharmaceuticals, Inc. (INNT) was downgraded to E+ from D- on 2/24/2020 due to a decline in the growth index, solvency index and volatility index. Earnings per share declined from -$0.1321 to -$0.257, the quick ratio declined from 1.39 to 0.68, and EBIT declined 6.28% from -$6.12M to -$6.51M.
D
Sell
8/13/2019Upgraded
Innovate Biopharmaceuticals, Inc. (INNT) was upgraded to D- from E+ on 8/13/2019 due to a noticeable increase in the growth index, solvency index and valuation index. Debt to equity declined from 2.34 to 0.82, the quick ratio increased from 1.05 to 1.39, and earnings per share increased from -$0.1627 to -$0.1321.
Innovate Biopharmaceuticals, Inc. (INNT) was upgraded to D- from E+ on 8/13/2019 due to a noticeable increase in the growth index, solvency index and valuation index. Debt to equity declined from 2.34 to 0.82, the quick ratio increased from 1.05 to 1.39, and earnings per share increased from -$0.1627 to -$0.1321.
E
Sell
7/5/2019Downgrade
Innovate Biopharmaceuticals, Inc. (INNT) was downgraded to E+ from D- on 7/5/2019 due to a decline in the solvency index, valuation index and volatility index. Debt to equity increased from -1.42 to 2.36.
Innovate Biopharmaceuticals, Inc. (INNT) was downgraded to E+ from D- on 7/5/2019 due to a decline in the solvency index, valuation index and volatility index. Debt to equity increased from -1.42 to 2.36.
D
Sell
5/1/2019Upgraded
Innovate Biopharmaceuticals, Inc. (INNT) was upgraded to D- from E+ on 5/1/2019 due to an increase in the valuation index, solvency index and growth index. Debt to equity declined from 13.63 to -1.42, and operating cash flow increased 30.79% from -$3.48M to -$2.41M.
Innovate Biopharmaceuticals, Inc. (INNT) was upgraded to D- from E+ on 5/1/2019 due to an increase in the valuation index, solvency index and growth index. Debt to equity declined from 13.63 to -1.42, and operating cash flow increased 30.79% from -$3.48M to -$2.41M.
E
Sell
10/1/2018Upgraded
Innovate Biopharmaceuticals, Inc. (INNT) was upgraded to E+ from E on 10/1/2018 due to an increase in the growth index, solvency index and valuation index. Earnings per share increased from -$0.7605 to -$0.1641, EBIT increased 73.04% from -$12.52M to -$3.38M, and operating cash flow increased 66.8% from -$6.97M to -$2.31M.
Innovate Biopharmaceuticals, Inc. (INNT) was upgraded to E+ from E on 10/1/2018 due to an increase in the growth index, solvency index and valuation index. Earnings per share increased from -$0.7605 to -$0.1641, EBIT increased 73.04% from -$12.52M to -$3.38M, and operating cash flow increased 66.8% from -$6.97M to -$2.31M.
E
Sell
7/2/2018Upgraded
9 Meters Biopharma, Inc. (NMTRQ) was upgraded to E from E- on 07/02/2018.
9 Meters Biopharma, Inc. (NMTRQ) was upgraded to E from E- on 07/02/2018.
E
Sell
5/17/2018None
9 Meters Biopharma, Inc. (NMTRQ) was downgraded to E- from U on 05/17/2018.
9 Meters Biopharma, Inc. (NMTRQ) was downgraded to E- from U on 05/17/2018.
OTC PK
04/02/2025 1:55PM Eastern
Quotes delayed
